Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06536881 · ClinicalTrials.gov registry record · NA

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

A NA study of Breast Cancer and Early Stage Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06536881 is a NA study of Breast Cancer and Early Stage Breast Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06536881, a NA study of Breast Cancer and Early Stage Breast Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.

Interventions

  • BEHAVIORAL Fasting

Study Locations (1)

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-08-08
Est. Completion 2029-05
Phase NA

What the Registry Record Tells You About NCT06536881

The ClinicalTrials.gov registry entry for NCT06536881 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fasting is the first listed.

NCT06536881 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06536881 about?

NCT06536881 is a clinical study titled "Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming". This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.

What is the current status of trial NCT06536881?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-08-08. Estimated completion is 2029-05.

What conditions does trial NCT06536881 study?

This clinical trial studies the following conditions: Breast Cancer, Early Stage Breast Cancer.

What interventions are being tested in trial NCT06536881?

The interventions under investigation include: Fasting (BEHAVIORAL).

Who is sponsoring clinical trial NCT06536881?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06536881 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.